MCL1 and acute myeloid leukemia: This synergistic effect was consistently observed across all primary AML patient samples analyzed.<h4>Conclusion</h4>The findings suggest that the combination of VEN and DHA exerts synergistic anti-leukemic effects by targeting BCL-XL, MCL-1 and C-MYC, offering a promising therapeutic strategy for AML.